Salem Partners
VC Fund
Los Angeles, United States
Salem Partners is a leading Los Angeles-based investment bank and wealth management firm. They build relationships using their judgment, objectivity and expertise to create significant long-term value for their clients.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 33%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Salem Partners invests in
Stages Salem Partners invests in
Countries Salem Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
William B. Witte
|
|||
John Dyett
|
|||
3 more contacts available
Investment Focus
Industry
- Biotechnology 6 (40%)
- Health Care 4 (27%)
- Software 3 (20%)
- Medical 2 (13%)
- Therapeutics 2 (13%)
Stage
- Series A 4 (27%)
- Series B 3 (20%)
- Series D 3 (20%)
- Convertible Note 2 (13%)
- Series C 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
William B. Witte
President
|
President | Total investments: 0 | Find email | |
|
John Dyett
Co-Founder and Managing Director
|
Co-Founder and Managing Director | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Rightsline
|
RightsLine provides software solutions to media and entertainment companies who need to track the full lifecycle of licensing and distribution deals around the world. Our solutions provide a transparent, codified way for content owners and content distributors to know exactly what the have to sell, on what terms, and for how long.Our software isbuilt on industry leading technology in a true multi tenant infrastructure, meaning our cost to deploy is a fraction of our competition.Our clients span across film, television, music, and publishing, but they all have one thing in common; the need to track the licensing deals they've done, when they expire, and what the terms and payments need to be.Leveraging cloud technologies and bringing an intuitive UI, RightsLine can handle any size library and any level of rights complexity. Examples of our client success cases include Disney, Turner, Google, Amazon Studios, Hulu, and a hundred others from the largest in the world to a single distributor. | Private Equity / May 27, 2026 | |
Fabric
|
Fabric is a cloud platform that enables customers to manage editorial, technical, and other metadata for television shows, movies, documentaries, games, and other media. With Fabric, you can easily connect your catalogue to new platforms, transform internal data processes, and deliver dramatically improved viewer and user experiences. | Series B / Dec 01, 2022 | |
Form Bio
|
Form Bio provides a variety of features, including workflows, data management, collaboration, data visualisation, and workflow catalogue. It provides solutions for lab directors, biotech, pharma, academics, and other fields. | $30M / Series A / Sep 27, 2022 | |
Onconano Medicine
|
OncoNano Medicine is a biotech company that develops nanotechnology-enabled fluorescent probes to help cancer surgeons visualize tumors during surgery, allowing them to excise tumors more precisely. The fluorescent sensor targets the different pH signals, thus making them glow so they are easier to distinguish from normal tissue.OncoNano Medicineis a UTSW spinoff company based in Dallas, Texas. | $68.4M / Convertible Note / Oct 02, 2021 | |
|
Fabric
|
Fabric is a cloud platform that enables customers to manage editorial, technical, and other metadata for television shows, movies, documentaries, games, and other media. With Fabric, you can easily connect your catalogue to new platforms, transform internal data processes, and deliver dramatically improved viewer and user experiences. | Series A / Jun 01, 2021 | |
|
Onconano Medicine
|
OncoNano Medicine is a biotech company that develops nanotechnology-enabled fluorescent probes to help cancer surgeons visualize tumors during surgery, allowing them to excise tumors more precisely. The fluorescent sensor targets the different pH signals, thus making them glow so they are easier to distinguish from normal tissue.OncoNano Medicineis a UTSW spinoff company based in Dallas, Texas. | $23.7M / Series A / Jul 09, 2019 | |
|
Rightsline
|
RightsLine provides software solutions to media and entertainment companies who need to track the full lifecycle of licensing and distribution deals around the world. Our solutions provide a transparent, codified way for content owners and content distributors to know exactly what the have to sell, on what terms, and for how long.Our software isbuilt on industry leading technology in a true multi tenant infrastructure, meaning our cost to deploy is a fraction of our competition.Our clients span across film, television, music, and publishing, but they all have one thing in common; the need to track the licensing deals they've done, when they expire, and what the terms and payments need to be.Leveraging cloud technologies and bringing an intuitive UI, RightsLine can handle any size library and any level of rights complexity. Examples of our client success cases include Disney, Turner, Google, Amazon Studios, Hulu, and a hundred others from the largest in the world to a single distributor. | Series D / Jun 14, 2019 | |
Lucid Sight
|
Lucid Sight is a computer software company that specializes in blockchain, augmented reality, and virtual reality. The company focuses on developing innovative monetization and marketing platforms for brands and game developers using emerging technologies. | $6M / Series B / Apr 02, 2019 | |
AsclepiX Therapeutics
|
AsclepiX Therapeutics represents the next generation of biologics and drug development technology. They use bioinformatics and systems biology methods to design classes of short biomimetic anti-angiogenic (anti-neovascular), and anti-lymphangiogenic peptides. They also use the latest developments in biomaterials and drug delivery to designlong-lasting biodegradable nano and microparticles to deliver these biomimetic therapeutic peptides throughout the body.AsclepiX Therapeutics utilizes its platform technology for indications in ophthalmology, oncology, and for other angiogenesis and lymphangiogenesis-dependent diseases. | $5M / Convertible Note / Nov 13, 2018 | |
|
Onconano Medicine
|
OncoNano Medicine is a biotech company that develops nanotechnology-enabled fluorescent probes to help cancer surgeons visualize tumors during surgery, allowing them to excise tumors more precisely. The fluorescent sensor targets the different pH signals, thus making them glow so they are easier to distinguish from normal tissue.OncoNano Medicineis a UTSW spinoff company based in Dallas, Texas. | $11.7M / Series A / May 17, 2018 | |
| See all 15 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Salem Partners invest in?
Salem Partners invests primarily in Biotechnology, Health Care and Software startups, most often at Series A and Series B stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Salem Partners?
Public channels for Salem Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Salem Partners?
The team at Salem Partners includes William B. Witte (President) and John Dyett (Co-Founder and Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
